DOCSLIB.ORG

Medicaid-Approved Preferred Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicaid-Approved Preferred Drug List New Jersey Medicaid-Approved Preferred Drug List Effective August 15, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay AL; QL 12 hour *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera DO; AL; QL *AMPHETAMINE MIXTURES*** amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 Adderall XR DO; AL; QL mg amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 Adderall XR AL; QL mg amphetamine-dextroamphetamine oral Adderall DO; AL; QL tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg amphetamine-dextroamphetamine oral Adderall AL tablet 20 mg, 30 mg *AMPHETAMINES*** dextroamphetamine sulfate er oral capsule Dexedrine AL; QL extended release 24 hour dextroamphetamine sulfate oral tablet 10 mg Zenzedi AL; QL dextroamphetamine sulfate oral tablet 5 mg Zenzedi DO; AL; QL *ANALEPTICS*** caffeine citrate intravenous solution Cafcit caffeine citrate oral solution *LIPASE INHIBITORS*** ALLI ORAL CAPSULE PA; OTC; QL *STIMULANTS - MISC.*** dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 Focalin XR DO; AL; QL mg, 5 mg dexmethylphenidate hcl er oral capsule extended release 24 hour 25 mg, 30 mg, 35 Focalin XR AL; QL mg, 40 mg dexmethylphenidate hcl oral tablet 10 mg Focalin AL; QL dexmethylphenidate hcl oral tablet 2.5 mg Focalin DO; AL; QL 2 Drug Name Reference Notes dexmethylphenidate hcl oral tablet 5 mg Focalin PA; DO; QL methylphenidate hcl er (cd) oral capsule DO; AL; QL extended release 10 mg, 20 mg, 30 mg methylphenidate hcl er (cd) oral capsule AL; QL extended release 40 mg, 50 mg, 60 mg methylphenidate hcl er (la) oral capsule Ritalin LA AL; QL extended release 24 hour methylphenidate hcl er oral tablet extended DO; AL; QL release 10 mg methylphenidate hcl er oral tablet extended Concerta DO; AL; QL release 18 mg, 27 mg methylphenidate hcl er oral tablet extended AL; QL release 20 mg methylphenidate hcl er oral tablet extended DO; AL; QL release 24 hour 18 mg, 27 mg methylphenidate hcl er oral tablet extended AL; QL release 24 hour 36 mg, 54 mg methylphenidate hcl er oral tablet extended Concerta AL; QL release 36 mg, 54 mg methylphenidate hcl oral solution Methylin AL methylphenidate hcl oral tablet 10 mg, 5 mg Ritalin DO; AL; QL methylphenidate hcl oral tablet 20 mg Ritalin AL *ALTERNATIVE MEDICINES* *ALTERNATIVE MEDICINE - ME'S*** cvs melatonin extra strength oral liquid OTC cvs melatonin gummies oral tablet chewable VitaJoy Gummies OTC cvs melatonin oral capsule OTC cvs melatonin oral liquid OTC cvs melatonin oral tablet 3 mg OTC cvs melatonin oral tablet 5 mg OTC; QL cvs melatonin oral tablet dispersible OTC cvs melatonin sublingual tablet sublingual OTC cvs quality sleep oral capsule OTC gnp melatonin maximum strength oral tablet OTC; QL gnp melatonin oral tablet OTC gnp melatonin oral tablet chewable VitaJoy Gummies OTC gnp melatonin sublingual tablet sublingual OTC hm melatonin quick dissolve oral tablet OTC dispersible 3 Drug Name Reference Notes hm melatonin sublingual tablet sublingual OTC kp melatonin oral tablet OTC max melatonin oral tablet dispersible OTC Zarbees Sleep melatonin childrens oral tablet chewable OTC Child/Melatonin melatonin er oral tablet extended release OTC melatonin extra strength oral liquid OTC melatonin gummies oral tablet chewable VitaJoy Gummies OTC melatonin maximum strength oral tablet 10 OTC mg melatonin maximum strength oral tablet 5 OTC; QL mg melatonin oral capsule OTC Zarbees Sleep melatonin oral liquid OTC Child/Melatonin melatonin oral tablet 1 mg, 10 mg, 3 mg, 300 OTC mcg melatonin oral tablet 5 mg OTC; QL melatonin oral tablet chewable VitaJoy Gummies OTC melatonin oral tablet dispersible OTC melatonin quick dissolve sublingual tablet OTC sublingual melatonin sublingual tablet sublingual OTC melatonin tr oral tablet extended release OTC mm melatonin oral tablet extended release OTC qc melatonin max st oral tablet OTC; QL ra melatonin oral tablet 10 mg, 3 mg OTC ra melatonin oral tablet 5 mg OTC; QL sm melatonin oral tablet OTC sm melatonin oral tablet dispersible OTC sv melatonin oral tablet OTC; QL sv melatonin oral tablet dispersible OTC VITAJOY GUMMIES ORAL TABLET OTC CHEWABLE ZARBEES SLEEP CHILD/MELATONIN OTC ORAL LIQUID *AMINOGLYCOSIDES* *AMINOGLYCOSIDES*** neomycin sulfate oral tablet 4 Drug Name Reference Notes paromomycin sulfate oral capsule Humatin tobramycin inhalation nebulization solution Kitabis Pak SP; QL *ANALGESICS - ANTI- INFLAMMATORY* *ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES*** HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE PA; SP; QL KIT HUMIRA PEN SUBCUTANEOUS PEN- PA; SP; QL INJECTOR KIT HUMIRA PEN-CD/UC/HS STARTER PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PEDIATRIC UC START PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PS/UV/ADOL HS START PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA PEN-PSOR/UVEIT STARTER PA; SP; QL SUBCUTANEOUS PEN-INJECTOR KIT HUMIRA SUBCUTANEOUS PREFILLED PA; SP; QL SYRINGE KIT *GOLD COMPOUNDS*** RIDAURA ORAL CAPSULE *NONSTEROIDAL ANTI- INFLAMMATORY AGENTS (NSAIDS)*** ADDAPRIN ORAL TABLET PA; OTC; QL ADVIL JUNIOR STRENGTH ORAL OTC TABLET ADVIL JUNIOR STRENGTH ORAL OTC TABLET CHEWABLE ADVIL LIQUI-GELS MINIS ORAL OTC CAPSULE all day pain relief oral tablet Mediproxen OTC; QL all day relief oral tablet Mediproxen OTC; QL childrens ibuprofen 100 oral suspension Childrens Medi-Profen OTC; QL childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL CHILDRENS MEDI-PROFEN ORAL OTC; QL SUSPENSION cvs all day pain relief oral tablet Mediproxen OTC; QL 5 Drug Name Reference Notes cvs childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL cvs ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL cvs ibuprofen infants oral suspension Medi-Profen OTC; QL cvs ibuprofen junior strength oral tablet Advil Junior Strength OTC chewable cvs ibuprofen oral capsule Advil Liqui-Gels minis OTC cvs ibuprofen oral tablet Addaprin OTC; QL cvs naproxen sodium oral capsule Aleve OTC cvs naproxen sodium oral tablet Mediproxen OTC; QL diclofenac potassium oral tablet Cataflam diclofenac sodium er oral tablet extended PA; QL release 24 hour diclofenac sodium oral tablet delayed QL release eq all day pain relief oral tablet Mediproxen OTC; QL eq ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL eq ibuprofen junior oral tablet chewable Advil Junior Strength OTC eq ibuprofen oral capsule Advil Liqui-Gels minis OTC eq ibuprofen oral tablet Addaprin OTC; QL eq naproxen sodium oral capsule Aleve OTC eq naproxen sodium oral tablet Mediproxen OTC; QL eql childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL eql ibuprofen infants oral suspension Medi-Profen OTC; QL eql ibuprofen junior strength oral tablet Advil Junior Strength OTC chewable eql ibuprofen oral capsule Advil Liqui-Gels minis OTC eql ibuprofen oral tablet Addaprin OTC; QL eql naproxen sodium oral capsule Aleve OTC eql naproxen sodium oral tablet Mediproxen OTC; QL etodolac er oral tablet extended release 24 QL hour etodolac oral capsule QL etodolac oral tablet Lodine QL fenoprofen calcium oral capsule Nalfon PA fenoprofen calcium oral tablet Nalfon flurbiprofen oral tablet QL gnp childrens ibuprofen oral suspension Childrens Medi-Profen OTC; QL gnp ibuprofen childrens oral tablet chewable Advil Junior Strength OTC 6 Drug Name Reference Notes gnp ibuprofen infants oral suspension Medi-Profen OTC; QL gnp ibuprofen oral capsule Advil Liqui-Gels minis OTC gnp ibuprofen oral tablet Addaprin OTC; QL gnp naproxen sodium oral capsule Aleve OTC gnp naproxen sodium oral tablet Mediproxen OTC; QL goodsense ibuprofen childrens oral Childrens Medi-Profen OTC; QL suspension goodsense ibuprofen infants oral suspension Medi-Profen OTC; QL goodsense ibuprofen oral capsule Advil Liqui-Gels minis OTC goodsense ibuprofen oral tablet Addaprin OTC; QL goodsense naproxen sodium oral tablet Mediproxen OTC; QL hm ibuprofen childrens oral suspension Childrens Medi-Profen OTC; QL hm ibuprofen ib oral tablet Addaprin OTC; QL hm ibuprofen ib oral tablet chewable Advil Junior Strength OTC hm ibuprofen infants oral suspension Medi-Profen OTC; QL hm ibuprofen oral capsule Advil Liqui-Gels minis OTC hm ibuprofen oral tablet Addaprin OTC; QL hm naproxen sodium oral capsule Aleve OTC hm naproxen sodium oral tablet Mediproxen OTC; QL hy-vee all day relief oral tablet Mediproxen OTC; QL HYVEE IBUPROFEN CHILDRENS ORAL OTC; QL SUSPENSION IBU ORAL TABLET QL ibu-200 oral tablet Addaprin PA; OTC; QL ibuprofen 100 junior strength oral tablet Advil Junior Strength OTC chewable ibuprofen childrens oral suspension Childrens Medi-Profen
Load more

Recommended publications
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Cilostazol Protects Rats Against Alcohol‑Induced Hepatic Fibrosis Via Suppression of TGF‑Β1/CTGF Activation and the Camp/Epac1 Pathway
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 2381-2388, 2019 Cilostazol protects rats against alcohol‑induced hepatic fibrosis via suppression of TGF‑β1/CTGF activation and the cAMP/Epac1 pathway KUN HAN, YANTING ZHANG and ZHENWEI YANG Department of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi 710003, P.R. China Received July 2, 2018; Accepted November 23, 2018 DOI: 10.3892/etm.2019.7207 Abstract. Alcohol abuse and chronic alcohol consump- Introduction tion are major causes of alcoholic liver disease worldwide, particularly alcohol‑induced hepatic fibrosis (AHF). Liver Liver fibrosis is a wound‑healing response to a variety of liver fibrosis is an important public health concern because of its insults, including excessive alcohol intake. Alcohol abuse and high morbidity and mortality. The present study examined chronic alcohol consumption are major causes of alcoholic the mechanisms and effects of the phosphodiesterase III liver disease (ALD) worldwide (1). Alcohol‑induced hepatic inhibitor cilostazol on AHF. Rats received alcohol infu- fibrosis (AHF) may cause serious hepatic cirrhosis, and is sions via gavage to induce liver fibrosis and were treated widely accepted as a milestone event in ALD (2). However, with colchicine (positive control) or cilostazol. The serum recent evidence indicates that liver fibrosis is reversible and alcohol dehydrogenase (ADH) and acetaldehyde dehydro- that the liver may recover from cirrhosis (3). Therefore, eluci- genase (ALDH) activities and the albumin/globulin (A/G), dation of the cellular and molecular mechanisms is urgently enzymes and hyaluronic acid (HA), type III precollagen required to prevent AHF. (PC III), laminin (LA), and type IV collagen (IV‑C) levels The exact mechanism remains unclear, but certain changes were measured using commercially available kits.
    [Show full text]
  • Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1
    [CANCER RESEARCH 49, 3168-3172, June 15, 1989] Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1 David L. McCormick,2 Ann M. Spicer, and Jacqueline L. Hollister Life Sciences Department, IIT Research Institute, Chicago, Illinois 60616 ABSTRACT studies with this class of compounds used inhibitors of the cyclooxygenase pathway of arachidonic acid catabolism; exper Neoplastic development in the rat mammary gland can be suppressed iments performed in our laboratory and by Ip and coworkers by inhibition of the activity of several enzymes involved in eicosanoid biosynthesis. In order to investigate the potential utility of prostacyclin demonstrated that the postcarcinogen phase of rat mammary and thromboxane synthetases as targets for mammary cancer chemopre- carcinogenesis can be suppressed by dietary administration of vention, experiments were conducted to determine the influence of tran- indomethacin (7, 8) or flurbiprofen (9). However, although the ylcypromine (TCP), an inhibitor of prostacyclin synthetase, and ¡mida/ole anticarcinogenic activity of indomethacin is similar to that of (IMI), an inhibitor of thromboxane synthetase, on mammary carcinogen- more widely studied inhibitors of mammary carcinogenesis such esis induced in rats by 7V-methyl-/V-nitrosourea. Fifty-day-old female as retinyl acetate (10) and selenium (11), the dose levels of Sprague-Dawley |Hsd:SD(BR)l rats received a single s.c. dose of 0 or 40 indomethacin required for chemopreventive efficacy in rats are mg of .V-mcth>l-.Y-nitrosoiirea per kg of body weight. Beginning 7 days close to the threshold of lethal toxicity (12). For this reason, after carcinogen administration, groups of rats were fed isoenergetic, studies are ongoing to identify additional modifiers of arachi casein-based diets containing 3 or 20% corn oil (w/w), supplemented with donic acid metabolism whose administration provides an effec (per kg of diet) 10 mg of TCP, 1000 mg of IMI, or sucrose carrier only.
    [Show full text]
  • Curative Effect of Selenium Against Indomethacin-Induced Gastric Ulcers in Rats
    J. Microbiol. Biotechnol. (2011), 21(4), 400–404 doi: 10.4014/jmb.1012.12019 First published online 19 January 2011 Curative Effect of Selenium Against Indomethacin-Induced Gastric Ulcers in Rats Kim, Jeong-Hwan1, Byung-Woo Kim1,3,4, Hyun-Ju Kwon1,3,4, and Soo-Wan Nam1,2,4* 1Department of Biomaterial Control, 2Department of Biotechnology and Bioengineering, 3Department of Life Science and Biotechnology, and 4Blue-Bio Industry RIC, Dong-Eui University, Busan 614-714, Korea Received: December 16, 2010 / Revised: December 30, 2010 / Accepted: December 31, 2010 Indomethacin is a nonsteroid anti-inflammatory agent erosions, ulcerative lesions, and petechial bleeding in the that is known to induce severe gastric mucosal lesions. In mucosa of stomach as serious side effects [10, 18]. According this study, we investigated the effect of selenium on gastric to previous reports, the oral administration of indomethacin in mucosal lesions in rats. To confirm the curative effect of rats causes ulcerative lesions in the gastric mucosa [7, 13]. selenium against indomethacin-induced gastric ulcers, Furthermore, the development of the gastric mucosal lesions gastric ulcers were induced by oral administration of induced by indomethacin is mainly mediated through 25 mg/kg indomethacin, and then different doses (10, 50, generation of oxygen free radicals and lipid peroxidation and 100 µg/kg of body weight) of selenium or vehicle were [6, 22, 25, 26, 28, 29]. treated by oral gavage for 3 days. Oral administration of Selenium is an essential nutrient of fundamental importance indomethacin clearly increased the gastric ulcer area in to human biology. It has important metabolic functions in the stomach, whereas selenium applied for 3 days significantly animals, including protection of membrane lipids and decreased the gastric ulcer area in a dose-dependent macromolecules from oxidative damage produced by peroxides manner.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Potential Adverse Effects of Resveratrol: a Literature Review
    International Journal of Molecular Sciences Review Potential Adverse Effects of Resveratrol: A Literature Review Abdullah Shaito 1 , Anna Maria Posadino 2, Nadin Younes 3, Hiba Hasan 4 , Sarah Halabi 5, Dalal Alhababi 3, Anjud Al-Mohannadi 3, Wael M Abdel-Rahman 6 , Ali H. Eid 7,*, Gheyath K. Nasrallah 3,* and Gianfranco Pintus 6,2,* 1 Department of Biological and Chemical Sciences, Lebanese International University, 1105 Beirut, Lebanon; [email protected] 2 Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; [email protected] 3 Department of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar; [email protected] (N.Y.); [email protected] (D.A.); [email protected] (A.A.-M.) 4 Institute of Anatomy and Cell Biology, Justus-Liebig-University Giessen, 35392 Giessen, Germany; [email protected] 5 Biology Department, Faculty of Arts and Sciences, American University of Beirut, 1105 Beirut, Lebanon; [email protected] 6 Department of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O Box: 27272, United Arab Emirates; [email protected] 7 Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236 Beirut, Lebanon * Correspondence: [email protected] (A.H.E.); [email protected] (G.K.N.); [email protected] (G.P.) Received: 13 December 2019; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Due to its health benefits, resveratrol (RE) is one of the most researched natural polyphenols.
    [Show full text]
  • Common Name: SELENIUM SULFIDE HAZARD SUMMARY
    Common Name: SELENIUM SULFIDE CAS Number: 7446-34-6 RTK Substance number: 1653 DOT Number: UN 2657 Date: October 1995 Revision: October 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY * Selenium Sulfide can affect you when breathed in and by * If you think you are experiencing any work-related health passing through your skin. problems, see a doctor trained to recognize occupational * Selenium Sulfide should be handled as a CARCINOGEN- diseases. Take this Fact Sheet with you. -WITH EXTREME CAUTION. * Contact can irritate the eyes with possible eye damage. WORKPLACE EXPOSURE LIMITS * Breathing Selenium Sulfide can irritate the nose and The following exposure limits are for Selenium compounds throat. (measured as Selenium): * High exposure may cause headache, nausea, vomiting, garlic odor of the breath, metallic taste and coated tongue. OSHA: The legal airborne permissible exposure limit * Repeated exposure can cause pallor, nervousness and (PEL) is 0.2 mg/m3 averaged over an 8-hour mood changes. workshift. * Selenium Sulfide may damage the liver and kidneys. NIOSH: The recommended airborne exposure limit is IDENTIFICATION 0.2 mg/m3 averaged over a 10-hour workshift. Selenium Sulfide is a bright orange powder. It is used in medicated shampoos. ACGIH: The recommended airborne exposure limit is 3 0.2 mg/m averaged over an 8-hour workshift. REASON FOR CITATION * Selenium Sulfide is on the Hazardous Substance List * Selenium Sulfide may be a CARCINOGEN in humans. because it is regulated by OSHA and cited by ACGIH, There may be no safe level of exposure to a carcinogen, so DOT, NIOSH, NTP, DEP, HHAG and EPA. all contact should be reduced to the lowest possible level.
    [Show full text]
  • Role of Selenium in HIV Infection
    Role of selenium in HIV infection The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Stone, Cosby A, Kosuke Kawai, Roland Kupka, and Wafaie W Fawzi. 2010. “Role of Selenium in HIV Infection.” Nutrition Reviews 68 (11) (October 20): 671–681. doi:10.1111/j.1753-4887.2010.00337.x. Published Version doi:10.1111/j.1753-4887.2010.00337.x Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26951080 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Nutr Rev. Author manuscript; available in PMC 2011 November 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nutr Rev. 2010 November ; 68(11): 671±681. doi:10.1111/j.1753-4887.2010.00337.x. The Role of Selenium in HIV Infection Cosby A Stone, Kosuke Kawai, Roland Kupka, Wafaie W Fawzi Harvard School of Public Health Cosby A Stone, School of Public Health and School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA Kosuke Kawai, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA Roland Kupka, and Department of Nutrition, Harvard School of Public Health, Boston, MA, USA and United Nations Children’s Fund, Regional Office for West and Central Africa, Dakar, Senegal Wafaie W.
    [Show full text]
  • Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-Administration of Selenium/ Tribulus Terrestris Extract in Rats
    Int. J. Morphol., 38(5):1444-1454, 2020. Hepatotoxicity-Induced by the Therapeutic Dose of Acetaminophen and the Ameliorative Effect of Oral Co-administration of Selenium/ Tribulus terrestris Extract in Rats Hepatotoxicidad Inducida por la Dosis Terapéutica de Acetaminofén y el Efecto de Mejora de la Administración Conjunta de Extracto de Selenio Tribulus terrestris en Ratas Amin A. Al-Doaiss1,2 AL-DOAISS, A. A. Hepatotoxicity-induced by the therapeutic dose of acetaminophen and the ameliorative effect of oral co-administration of selenium / Tribulus terrestris extract in rats. Int. J. Morphol., 38(5):1444-1454, 2020. SUMMARY: Over dose or long-term clinical use of therapeutic doses of acetaminophen (APAP) causes hepatotoxicity. Various strategies attempted to ameliorate APAP-hepatotoxicity have been found to be unsuitable for clinical practice. This study was aimed to illustrate the histopathological changes induced by therapeutic dose of APAP and investigate the hepatoprotective role of oral co- administration of selenium/ Tribulus terrestris (TT) extract concurrently against hepatotoxicity induced by APAP in rats. Fifty-four healthy male albino Wistar rats were randomized into nine groups (G1–G9) of six rats each, and administered with APAP and TT orally for 30 days as follows: Control (2ml normal saline), APAP (470 mg/kg), APAP (470 mg/kg) + selenium (2 mg/kg), APAP (470 mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + selenium (2mg/kg) + TT (98 mg/kg), APAP (470 mg/kg) + silymarin (200 mg/kg), selenium (2 mg/ kg), TT (98 mg/kg) and silymarin (200 mg/kg) groups. The results demonstrated that exposure of rats to therapeutic dose of APAP for 30 days caused significant histopathological changes parallel to elevated blood chemistry parameters.
    [Show full text]
  • Cilostazol Tablets, USP50 Mg and 100 Mgrx Only
    CILOSTAZOL - cilostazol tablet Physicians Total Care, Inc. ---------- Cilostazol Tablets, USP 50 mg and 100 mg Rx only CONTRAINDICATION Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Cilostazol is contraindicated in patients with congestive heart failure of any severity. DESCRIPTION Cilostazol is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is C20H27N5O2, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, CAS-73963-72-1. The structural formula is: Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH. Cilostazol Tablets, USP for oral administration are available as 50 mg or 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hypromellose, magnesium stearate and microcrystalline cellulose. CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of the effects of Cilostazol Tablets, USP on the symptoms of intermittent claudication is not fully understood. Cilostazol Tablets, USP and several of its metabolities are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degration with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]